TransMedics Director David Weill Purchases $109,000 of Stock -- Should Investors Buy Too?
Key Points
The director acquired 1,336 shares for a total value of ~$109,000 on Sept. 11, 2026.
The purchase involved shares equal to 9% of the stake held before the filing.
The transaction was executed via direct ownership, bringing the total direct position to 16,392 shares.
Shares were purchased at $81.63 per share, while the stock was priced at $82.18 at the Sept. 11, 2026, market close.
- 10 stocks we like better than TransMedics Group ›
David Weill, a Director at TransMedics Group, Inc. (NASDAQ:TMDX), purchased 1,336 shares of common stock on Sept. 11, 2026. SEC Form 4 filing
Transaction summary
| Metric | Value |
|---|---|
| Transaction value | $109,000 |
| Shares purchased (directly held) | 1,336 |
| Post-transaction shares (directly held) | 16,392 |
| Post-transaction value | $1.35 million |
Transaction value based on SEC Form 4 weighted average purchase price ($81.63); post-transaction value based on Sept. 11, 2026, market close ($82.18).
Key questions
- How did this transaction affect the director's total equity stake?
The acquisition of 1,336 shares, representing 9% of the shares held prior to the filing, increased the total direct holdings to 16,392 shares. - What is the current market valuation of the insider's position?
Based on the Sept. 14, 2026, market close price of $85.86, David Weill's 16,392 shares are valued at ~$1.4 million. - What performance context surrounded the acquisition?
The purchase was executed as the stock recorded a one-year return of -30% through the Sept. 11, 2026, transaction date. - What are the primary operations of TransMedics Group?
The company is a commercial-stage medical technology enterprise that focuses on organ transplant therapy through its Organ Care System, which is designed to monitor and optimize donor organs.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-09-29) | $82.73 |
| Market Capitalization | $2.7 billion |
| Revenue (TTM) | $668.5 million |
| Net Income (TTM) | $151.7 million |
Company Snapshot
- TransMedics Group, Inc. develops and commercializes the Organ Care System (OCS), a portable medical device that perfuses, optimizes, and continuously monitors donor organs to improve transplant outcomes and expand the donor organ pool.
- The company generates revenue through the sale of OCS devices and related consumables, service agreements, and licensing arrangements with transplant centers and healthcare systems globally.
- TransMedics serves transplant centers, hospitals, and organ procurement organizations in North America and internationally, targeting institutions performing heart, lung, and liver transplantation procedures.
TransMedics Group is a commercial-stage medical technology enterprise with a market capitalization of $2.7 billion and TTM revenues of $668.5 million, demonstrating significant scale in the organ transplantation technology sector. The company's Organ Care System represents a differentiated approach to donor organ preservation, using proprietary perfusion technology to recreate near-physiological conditions and extend the viability window of organs. This innovation positions TransMedics as a critical enabler of expanded criteria donor utilization and improved transplant outcomes, providing a competitive advantage in addressing the substantial global shortage of viable donor organs.
What this transaction means for investors
While it is great to see some open-market purchases by a director at TransMedics, I wouldn't let the buy serve as anything more than a tiebreaker for investors considering scooping up a few shares.
First, while it is a positive sign, it was only a $109,000 purchase, so this isn't a groundbreaking figure in the context of the broader stock market. Sure, it's a ton of money to me, but in publicly traded stock terms for a multi-billion-dollar company, it isn't overwhelming.
That said, it is a nice vote of confidence from an insider at the company and reinforces the notion that management believes in TMDX stock's promising operations. TransMedics is guiding for 22%-25% sales growth in 2026 and remains the fastest-growing in its niche.
As TransMedics iterates upon its existing liver, heart, and lung platforms, tests a new kidney OCS, and continues expanding internationally while scaling its logistics unit, the company remains a buy in my eyes -- and Director Weills' purchase is a nice cherry on top for me.
Currently, TMDX stock trades at 22 times cash from operations, which isn't outrageous considering the company's long-term growth potential as it continues to revolutionize and modernize the organ donation process.
Should you buy stock in TransMedics Group right now?
Before you buy stock in TransMedics Group, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and TransMedics Group wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $373,352!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,406,241!*
Now, it’s worth noting Stock Advisor’s total average return is 933% — a market-crushing outperformance compared to 212% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of September 29, 2026.
Josh Kohn-Lindquist has positions in TransMedics Group. The Motley Fool has positions in and recommends TransMedics Group. The Motley Fool has a disclosure policy.
Recommended Articles
